Data / Drug companies / Precision Dose, Inc.
Precision Dose, Inc.: 77 products in the FDA NDC directory, labeler code 68094
Precision Dose, Inc. (labeler code 68094) lists 77 products in the FDA National Drug Code Directory, covering 39 finished drugs by generic name. By type: 59 prescription drugs, 17 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 9, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68094
- Products in commercial distribution
- 77
- Packages
- 110
- Finished drugs by generic name
- 39
- Prescription products
- 59
- Over the counter products
- 17
- Controlled substance products
- Schedule II 9, Schedule IV 7, Schedule V 2
- Flagged as original packager
- 29 of 29 products that carry the flag
- Started marketing in the last 12 months
- 4
- Products with a marketing end date set
- 5
- Earliest marketing start
- April 13, 2004
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 61 | 79.2% |
| Over the counter monograph drugs | 9 | 11.7% |
| New drug applications (NDA) | 6 | 7.8% |
| Drugs for further processing | 1 | 1.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 59 | 76.6% |
| Over the counter drugs | 17 | 22.1% |
| Drugs for further processing | 1 | 1.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Acetaminophen | 7 | 214 |
| Morphine sulfate | 6 | 31 |
| Metformin hydrochloride | 5 | 79 |
| Phentermine hydrochloride | 3 | 26 |
| Ibuprofen | 3 | 190 |
| Azithromycin dihydrate | 3 | 20 |
| Dexmedetomidine hydrochloride | 3 | 21 |
| Gabapentin | 3 | 91 |
| Methazolamide | 2 | 10 |
| Lacosamide | 2 | 57 |
| Midazolam hydrochloride | 2 | 19 |
| Cholestyramine | 2 | 14 |
| Megestrol acetate | 2 | 17 |
| Benzonatate | 2 | 42 |
| Furosemide | 2 | 63 |
| Naltrexone hydrochloride | 2 | 24 |
| Methadone hydrochloride | 2 | 21 |
| Tetrabenazine | 2 | 12 |
| Loperamide hydrochloride | 2 | 82 |
| Carbamazepine | 2 | 52 |
| Diphenhydramine hydrochloride | 1 | 127 |
| Fosfomycin tromethamine | 1 | 9 |
| Lidocaine hydrochloride | 1 | 134 |
| Cetirizine hcl | 1 | 48 |
| Senna | 1 | 6 |
| Guanfacine | 1 | 33 |
| Oxcarbazepine | 1 | 46 |
| Ondansetron hydrochloride | 1 | 48 |
| Sucralfate oral | 1 | 6 |
| Clobazam | 1 | 18 |
| Phentolamine mesylate | 1 | 4 |
| Sevelamer carbonate | 1 | 35 |
| Famotidine | 1 | 138 |
| Levetiracetam | 1 | 87 |
| Lithium citrate | 1 | 1 |
| Oxycodone hydrochloride | 1 | 36 |
| Diazepam | 1 | 51 |
| Guaifenesin | 1 | 123 |
| Glycopyrrolate | 1 | 64 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 20 | 26% |
| Suspension | 18 | 23.4% |
| Tablet | 8 | 10.4% |
| Tablet, film coated | 7 | 9.1% |
| Tablet, coated | 6 | 7.8% |
| Capsule | 4 | 5.2% |
| Syrup | 3 | 3.9% |
| Injection, solution | 3 | 3.9% |
| Powder, for suspension | 2 | 2.6% |
| Tablet, extended release | 2 | 2.6% |
| Granule | 1 | 1.3% |
| Injection | 1 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Carbamazepine | 68094-225 | Suspension | Generic drugs (ANDA) | October 9, 2026 |
| Carbamazepine | 68094-125 | Suspension | Generic drugs (ANDA) | October 9, 2026 |
| Fosfomycin Tromethamine | 68094-064 | Granule | Generic drugs (ANDA) | February 15, 2026 |
| Gabapentin | 68094-069 | Tablet, coated | Generic drugs (ANDA) | January 5, 2026 |
| Lithium | 68094-077 | Solution | Generic drugs (ANDA) | October 24, 2025 |
| Lacosamide | 68094-176 | Solution | Generic drugs (ANDA) | September 22, 2025 |
| Lacosamide | 68094-076 | Solution | Generic drugs (ANDA) | September 22, 2025 |
| Morphine Sulfate | 68094-556 | Solution | New drug applications (NDA) | September 1, 2025 |
| Glycopyrrolate | 68094-073 | Solution | Generic drugs (ANDA) | July 7, 2025 |
| Morphine Sulfate | 68094-156 | Solution | New drug applications (NDA) | June 6, 2025 |
| Clobazam | 68094-074 | Suspension | Generic drugs (ANDA) | March 10, 2025 |
| Sucralfate | 68094-041 | Suspension | Generic drugs (ANDA) | January 30, 2025 |
| Acetaminophen | 68094-042 | Suspension | Over the counter monograph drugs | January 13, 2025 |
| Lidocaine Hydrochloride | 68094-081 | Solution | Generic drugs (ANDA) | November 26, 2024 |
| Levetiracetam | 68094-313 | Injection, solution, concentrate | Generic drugs (ANDA) | October 10, 2024 |
| Senna | 68094-049 | Syrup | Over the counter monograph drugs | June 15, 2024 |
| Cholestyramine | 68094-806 | Powder, for suspension | Generic drugs (ANDA) | April 25, 2024 |
| Acetaminophen | 68094-075 | Suspension | Drugs for further processing | April 1, 2024 |
| Famotidine | 68094-054 | Tablet, film coated | Generic drugs (ANDA) | March 28, 2024 |
| Benzonatate | 68094-901 | Capsule | Generic drugs (ANDA) | March 1, 2024 |
| Benzonatate | 68094-798 | Capsule | Generic drugs (ANDA) | March 1, 2024 |
| Phentermine Hydrochloride | 68094-910 | Capsule | Generic drugs (ANDA) | February 15, 2024 |
| Naltrexone Hydrochloride | 68094-909 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2024 |
| Metformin Hydrochloride | 68094-904 | Tablet, extended release | Generic drugs (ANDA) | February 15, 2024 |
| Azithromycin Dihydrate | 68094-900 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2024 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.